RBF Capital LLC acquired a new stake in Allergan PLC. (NYSE:AGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 7,000 shares of the company’s stock, valued at approximately $1,672,000.
Other large investors have also added to or reduced their stakes in the company. First Financial Equity Corporation acquired a new stake in Allergan PLC. during the first quarter valued at about $465,000. Altavista Wealth Management Inc. increased its stake in Allergan PLC. by 16.0% in the first quarter. Altavista Wealth Management Inc. now owns 16,105 shares of the company’s stock valued at $3,848,000 after buying an additional 2,223 shares in the last quarter. Covington Capital Management increased its stake in Allergan PLC. by 12.7% in the first quarter. Covington Capital Management now owns 24,818 shares of the company’s stock valued at $5,930,000 after buying an additional 2,788 shares in the last quarter. IHT Wealth Management LLC increased its stake in Allergan PLC. by 17.2% in the first quarter. IHT Wealth Management LLC now owns 4,084 shares of the company’s stock valued at $971,000 after buying an additional 600 shares in the last quarter. Finally, Private Advisory Group LLC acquired a new stake in Allergan PLC. during the first quarter valued at about $246,000. Institutional investors own 83.63% of the company’s stock.
Shares of Allergan PLC. (NYSE:AGN) traded down 0.35% during mid-day trading on Friday, hitting $223.99. 2,006,235 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $243.31 and a 200-day moving average price of $238.68. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company has a market capitalization of $74.88 billion, a price-to-earnings ratio of 6.82 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the business earned $3.35 earnings per share. On average, equities analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. Allergan PLC.’s payout ratio is presently 9.95%.
TRADEMARK VIOLATION WARNING: This piece was published by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/7000-shares-in-allergan-plc-agn-acquired-by-rbf-capital-llc-updated.html.
Several equities research analysts have issued reports on the stock. BidaskClub downgraded shares of Allergan PLC. from a “hold” rating to a “sell” rating in a research note on Thursday. Argus reiterated a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday, August 14th. UBS AG reissued an “outperform” rating and set a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. Deutsche Bank AG reissued a “buy” rating and set a $278.00 target price (up from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $280.00 target price (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.